Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?
Author:
Tonello Marta1, Bison Elisa2, Cattini Maria Grazia2, Pontara Elena2, Iaccarino Luca1, Denas Gentian2, Cheng Chunyan2, Pengo Vittorio23ORCID
Affiliation:
1. Department of Medicine , Rheumatology Section, University of Padua , Padua , Italy 2. Thrombosis Research Laboratory , University of Padua , Padua , Italy 3. Arianna Foundation on Anticoagulation , Bologna , Italy
Abstract
Abstract
Objectives
Anti phosphatidylserine/prothrombin antibodies (aPS/PT) are often present in patients with antiphospholipid syndrome (APS) and might be relevant in the pathogenesis of this condition. They are major determinant of lupus anticoagulant (LA) in triple-positive antiphospholipid (aPL) profile. Whether they are present and pathogenic in patients with isolated LA [negative anticardiolipin (aCL) and anti β2-glycoprotein I (aβ2GPI) antibodies] is a matter of debate.
Methods
We measured aPS/PT in a large number of isolated LA with the aim to ascertain whether there is a link between the way isolated LA is assessed and the presence of these antibodies. APS/PT were measured in 86 patients with isolated LA (aCL- and abeta2GPI-). LA was assessed by two test systems, the dilute Russell Viper Venom Time (dRVVT) and the Silica Clotting Time (SCT).
Results
Sixty-six (77%) individuals with isolated LA were positive for aPS/PT (IgM 44, IgG and IgM 15, IgG in 7). Diagnosis of LA was made based on positive results in both dRVVT and SCT in 40 patients (Group 1) and based on only one positive test in the remaining 46 patients (Group 2). The rate of positive aPS/PT antibodies was significantly higher in Group 1 (OR=7.2, 95% CI 1.9–27.0, p<0.002). Moreover, the titre of IgM aPS/PT was significantly increased in Group 1 as compared to Group 2 (137 U, IQR 64–179 vs. 43 U, IQR 11–120, p=0.008).
Conclusions
These data indicate an association between LA based on two positive coagulation tests and the presence of aPS/PT antibodies, especially of IgM isotype.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference13 articles.
1. Tektonidou, MG, Andreoli, L, Limper, M, Amoura, Z, Cervera, R, Costedoat-Chalumeau, N, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296–304. https://doi.org/10.1136/annrheumdis-2019-215213. 2. Pengo, V, Del Ross, T, Ruffatti, A, Bison, E, Cattini, MG, Pontara, E, et al.. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res 2018;172:172–8. https://doi.org/10.1016/j.thromres.2018.11.003. 3. Pengo, V, Testa, S, Martinelli, I, Ghirarduzzi, A, Legnani, C, Gresele, P, et al.. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2015;135:46–9. https://doi.org/10.1016/j.thromres.2014.10.013. 4. Yin, D, de Groot, PG, Ninivaggi, M, Devreese, KMJ, de Laat, B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome. Thromb Haemostasis 2020. https://doi.org/10.1055/a-1344-4271. [Online ahead of print]. 5. Pengo, V. Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome: response from Pengo. J Thromb Haemostasis 2020;18:3118–9. https://doi.org/10.1111/jth.15026.
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|